Shelia Violette
Founder at Q32 Bio, Inc.
Net worth: 56 904 $ as of 29/04/2024
Network origin in Shelia Violette first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Yale University
529
| College/University | Other Consumer Services | 529 |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.
75
| Private Company | Investment Managers | 75 |
Q32 Bio, Inc.
 Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA.
15
| Subsidiary | Biotechnology | 15 |
CytImmune Sciences, Inc.
 CytImmune Sciences, Inc. BiotechnologyHealth Technology CytImmune Sciences, Inc. operates as a clinical stage oncology company. It develops and manufactures cytokine immunoassay kits. The company was founded by Lawrence Tamarkin and Giulio F. Paciotti in 1998 and is headquartered in Rockville, MD.
1
| Extinct | Biotechnology | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Shelia Violette via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Atlas Venture Life Science Advisors LLC
 Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Director of Finance/CFO Consultant / Advisor Consultant / Advisor Private Equity Investor Consultant / Advisor Consultant / Advisor | |
Nimbus Therapeutics LLC
 Nimbus Therapeutics LLC BiotechnologyHealth Technology Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Founder Director/Board Member Corporate Officer/Principal Consultant / Advisor Chief Operating Officer Director/Board Member Chief Executive Officer Chief Executive Officer Private Equity Investor | |
Disarm Therapeutics, Inc.
 Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Biotechnology | Chief Executive Officer Consultant / Advisor Founder Private Equity Investor Corporate Officer/Principal Consultant / Advisor Chief Tech/Sci/R&D Officer Private Equity Investor | |
| KYMERA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Founder Director/Board Member Director/Board Member Director/Board Member Founder Private Equity Investor | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Masters Business Admin Doctorate Degree Undergraduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| GENERATION BIO CO. | Pharmaceuticals: Major | Founder Chief Executive Officer Chief Tech/Sci/R&D Officer Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
| THIRD HARMONIC BIO, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Director/Board Member Director/Board Member Corporate Officer/Principal | |
HotSpot Therapeutics, Inc.
 HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Biotechnology | Chairman Consultant / Advisor Founder Director/Board Member Founder Corporate Officer/Principal | |
Annovation BioPharma, Inc.
 Annovation BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Annovation BioPharma, Inc. develops pharmaceutical products in the field of anesthesia, sedation and sleep. It is developing a rapid-acting anesthesia called Rapidate. The firm's novel agents are designed to allow more precise control of anesthesia and enable safer treatment of patients undergoing surgical procedures. The company was founded in 2009 by Nicholas Barker and is headquartered in Parsippany, NJ. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Founder Director/Board Member Corporate Officer/Principal | |
Navitor Pharmaceuticals, Inc.
 Navitor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member | |
| Stanford University | College/University | Undergraduate Degree Masters Business Admin Graduate Degree Doctorate Degree Graduate Degree | |
Nimbus Apollo, Inc.
 Nimbus Apollo, Inc. Pharmaceuticals: MajorHealth Technology Nimbus Apollo, Inc. provides drug discovery research services. The company is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Director/Board Member Chief Executive Officer | |
Matchpoint Therapeutics, Inc.
 Matchpoint Therapeutics, Inc. BiotechnologyHealth Technology Matchpoint Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company aims to discover and develop precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. Matchpoint's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry library evolution. The company was founded by Jianwei Che, Edward Chouchani, Tinghu Zhang, Nathanael S. Gray, and the CEO is G. Andre Turenne. | Biotechnology | Chairman Chief Tech/Sci/R&D Officer Director/Board Member Chief Executive Officer Chief Invt Officer-Spezialfond | |
Rectify Pharmaceuticals LLC
 Rectify Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture. | Miscellaneous Commercial Services | Chairman Director/Board Member Chief Executive Officer Founder Consultant / Advisor | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Doctorate Degree | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Director/Board Member Corporate Officer/Principal Private Equity Investor | |
| Harvard Medical School | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree | |
| SURFACE ONCOLOGY, INC. | Biotechnology | Chief Executive Officer Chief Tech/Sci/R&D Officer Director/Board Member Chief Operating Officer | |
Rodin Therapeutics, Inc.
 Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Biotechnology | Chief Executive Officer Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
Arteaus Therapeutics LLC
 Arteaus Therapeutics LLC BiotechnologyHealth Technology Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA. | Biotechnology | Founder Chief Executive Officer Founder Corporate Officer/Principal | |
Korro Bio, Inc.
 Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Biotechnology | Founder Director/Board Member Private Equity Investor Chief Executive Officer | |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| VIGIL NEUROSCIENCE, INC. | Biotechnology | Chief Executive Officer Chairman Private Equity Investor Director/Board Member | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Private Equity Investor | |
K36 Therapeutics, Inc.
 K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Chief Executive Officer | |
Scorpion Therapeutics, Inc.
 Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| INFINITY PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| DYNE THERAPEUTICS, INC. | Biotechnology | Founder Chief Executive Officer Chief Tech/Sci/R&D Officer | |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal President Corporate Officer/Principal | |
| SPERO THERAPEUTICS, INC. | Biotechnology | Director/Board Member Founder Chief Operating Officer | |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Analyst Private Equity Investor | |
| TRANSLATE BIO, INC. | Biotechnology | Founder Director/Board Member Director/Board Member | |
| RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Director/Board Member | |
| University of Notre Dame | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chairman Founder Chief Executive Officer | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Santi Therapeutics, Inc.
 Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Founder | |
Disc Medicine Opco, Inc.
 Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | Biotechnology | Chief Executive Officer Chairman Private Equity Investor | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Corporate Officer/Principal |
Statistics
International
| United States | 50 |
| United Kingdom | 2 |
Sectoral
| Health Technology | 39 |
| Consumer Services | 8 |
| Finance | 4 |
| Commercial Services | 3 |
Operational
| Director/Board Member | 516 |
| Corporate Officer/Principal | 248 |
| Independent Dir/Board Member | 118 |
| Chief Executive Officer | 96 |
| Chairman | 96 |
Most connected contacts
| Insiders | |
|---|---|
| Jean-Francois Formela | 47 |
| Bruce Booth | 40 |
| Stephen P. Squinto | 40 |
| Peter Barrett | 38 |
| John Maraganore | 38 |
| Ryan Moore | 38 |
| Christopher Lynch | 38 |
| Kevin Bitterman | 36 |
| Kathy LaPorte | 34 |
| Shelley Chu | 31 |
| Patrick Ennis | 30 |
| Mark Iwicki | 26 |
| Jason Rhodes | 24 |
| Dave Grayzel | 23 |
| Ankit Mahadevia | 23 |
- Stock Market
- Insiders
- Shelia Violette
- Company connections
